Voluntary announcement first subject enrolled in phase i clinical trial of BA1203 (a masked anti-PD-1/IL-2 fusion protein) in china
Filed with HKEX · Stock code 6955 ·
6ix is reading this filing.
View original source (HKEXnews)Shandong Boan Biotechnology Company., Limited on 6ix
Earlier from Shandong Boan Biotechnology
- Continuing connected transactions promotion cooperation agreement
- Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2026
- Interim report 2026
- Next Day Disclosure Return
- Voluntary announcement cde approval of IND application for BA1203 (a masked anti-PD-1/IL-2 fusion protein)
Follow Shandong Boan Biotechnology into a list and get an email when it puts out news.
Follow Shandong Boan Biotechnology